Immune Checkpoint Therapeutics – Hot Targets & Pipeline Analysis

Immune Checkpoint Therapeutics – Hot Targets & Pipeline Analysis gives comprehensive insights on the various Immune Checkpoint modulators being developed for the treatment of various diseases. The report covers all the drugs being developed in various phases (Discovery, Preclinical, Clinical development & Marketed). The pipeline focuses on novel medicines covering small molecules, monoclonal antibodies, Recombinant proteins, Bi-specific Ab’s, Antibody drug conjugates, Cell therapy, Peptides, Oncolytic viruses and Vaccines. The report also covers hot targets in research for Checkpoint modulators.

This report enables Pharmaceutical /Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the Immune Checkpoints Drug market. The report also provides strategic insights on medicines that are likely to have an impact on future Immune Checkpoint treatment space. The report in addition to the monotherapy covers the pipeline for combination therapies associated only with checkpoint agents.

In order to effectively deal various diseases, the immune system needs to be able to generate an appropriate counter response. However, as a part of the natural fail–safe mechanism, to limit overactive immune responses that could lead to an auto-immune disease, there are a number of markers (“immune checkpoint receptors”) found on both tumor cells and antigen presenting cells (dendritic cells, macrophages etc.) that can down-regulate or suppress T cells once the corresponding ligand is bound. Currently, Researchers are challenged to identify various avenues to prevent T cells from binding these tolerance-inducing ligands either through antibodies or recombinant forms of ligand or receptors. So, these T cells remain active and ready to tackle various diseases. Owing to its high response rate and prolonged overall patient survival the checkpoint therapeutics are gaining in popularity and have shown some impressive results in the areas of Oncology, Inflammation, Respiratory, Autoimmune and Infectious disease.

Since, the approval of BMS ipilimumab (Yervoy) and Merck’s Pembrolizumab (Keytruda) for the treatment of patients with metastatic melanoma, the targeting of immune checkpoints has become the prime focus of several leading academic and industry players. The field of Checkpoint therapy has been successful in attracting some of the biggest pharmaceutical & Biotech companies. These players are forging alliances with several small biotech’s and academic institutes to discover new and more effective ways of exploiting the power of the body’s own immune system in fighting tumors.

Large Pharmaceutical/Biotech companies like AstraZeneca, BMS, Roche, Innate Pharma, Incyte Corporation and MSD are ahead of other companies with their marketed compounds as well as strong pipelines and are considered as leaders in this space. While, companies like Agenus, Compugen, Apogenix, Baxalta, Macrogenics, Aduro Biotech etc., benefit from this race of large pharma/biotechs via asset acquisition, research collaboration or Co-development

Key Findings:

• The global Immune Checkpoint therapeutics market is estimated to be $xx billion in 2015 with the approval of new drugs and is expected to grow at a CAGR of high-range double digit from 2016 to 2022 to reach $xx billion by 2022
• Factors contributing to the market growth include, Launch of approved drugs, technological advancements leading to emergence of novel therapeutics & mechanisms, increase in investments, increasing incidence of cancers and low survival rates .
• IQ4I analysis indicates that 31.7% of candidates are in Pre-clinical stage followed by xx% in PI clinical
• In addition to small molecules, there is growing interest among researchers on large molecules and novel therapies, such as

• Monoclonal antibody-based therapy
• Recombinant proteins
• Bi-specific Ab’s
• Antibody drug conjugates
• Cell therapy
• Peptides
• Oncolytic viruses and
• Vaccines

Some of the key sections covered in the report are given below:

Hot Targets, Mechanisms & Therapies

In this section, various Immune Checkpoint related targets, mechanism and upcoming therapies are discussed. Also, covers novel targets in early research along with pipeline.

Market analysis

In market analysis section, global Immune Checkpoint drugs market is indicated along with the forecasted values from 2016-2022.

• Forecasting model for Immune Checkpoint market
• Immune Checkpoint market dynamics
• Immune Checkpoint related deals analysis with financials (Acquisitions, Co-development, Joint-Ventures etc)

Pipeline Analysis

Pipeline analysis was carried to get deeper insights on various treatment modalities in discovery, preclinical & development section, pipelines from major companies were identified and Potential targets were reported along with Mechanism of action, Current development status & nature of molecule. Covers both Monotherapy and Combinations

• Pipeline analysis by developmental stage (Discovery to Clinical development)
• Pipeline analysis by modalities
  • Monoclonal antibody-based therapy
  • Recombinant proteins
  • Bi-specific Ab’s
  • Antibody drug conjugates
  • Cell therapy
  • Peptides
  • Oncolytic viruses and
  • Vaccines
• Pipeline analysis by leading players & Target analysis
• Drug analysis based on mechanism.

Key Players Analysis

The key player’s analysis section provides an in-depth understanding of various companies working on Immune Checkpoints and their Pipelines with development phase as well as understanding partnering strategies such as deals entered by the company.

• Global key players overview
• Global key players Pipeline data (Discovery, Pre-clinical, Clinical development & Marketed)

Global key players deals (Collaborations, Licensing, Service agreements, grants, funds)